Professional Documents
Culture Documents
DCL en La Practica Clínica
DCL en La Practica Clínica
Abstract
The spectrum of cognitive decline in the elderly ranges from what can be classified as normal cognitive decline with aging to
subjective cognitive impairment to mild cognitive impairment (MCI) to dementia. This article reviewed the up-to-date evidence of
MCI including the diagnostic criteria of MCI due to Alzheimer’s disease, vascular cognitive impairment and MCI due to Parkinson
disease, management and preventive intervention of MCI. There are various etiologies of MCI, and a large number of studies have
been conducted to ascertain the practical modalities of preserving cognition in predementia stages. Lifestyle modification, such as
aerobic exercise, is an approved modality to preserve cognitive ability and decrease the rate of progression to dementia, as well as
being recommended for frailty prevention.
Keywords
Alzheimer’s disease, cognitive impairment, frailty, geriatric syndrome, predementia, MCI, minor neurocognitive disorder
pharmacological and nonpharmacological management and level of education did affect the MMSE score, particularly in
prevention of MCI. no-memory scores (orientation, attention, and language)
among older Mexican Americans.22,26,27 Furthermore, a study
comparing the characteristic differences in the MMSE used
Prevalence of MCI across Asian countries found that it was an unstandardized
Mild cognitive impairment or mild neurocognitive disorder is cognitive tool due to a variety in administration and con-
an intermediate state9-15 between normal aging and dementia. tents.28 For the usefulness of the DRS in identifying persons
This state can progress to dementia, mostly in the form of with MCI, though it could predict declined function and inci-
Alzheimer’s disease.16,17 The prevalence of MCI in adults dent of dementia in some studies,29,30 Clinical dementia rat-
older than 60 is approximately 6.7% to 25.2%. It increases with ing (CDR) scores did not have a good correlation with MCI.31
age and lower level of education and is more prevalent in An overall score of 0.5 veiled the diverse functional status of
men.9-12 The prevalence is varied due to differences in defini- individuals. Some persons with MCI based on the DRS had
tions of MCI used in most studies. Formerly, MCI was defined extensive brain pathology and poorer episodic memory and
by focusing mainly on amnesia, but it later includes a wider executive functions and greater risk of developing dementia;
definition that covers either impairment in single-domain non- therefore, using global CDR alone appears to be an imperfect
amnestic or several cognitive domains with or without memory tool for detecting MCI.32 The Cochrane Database of Systema-
deficit.9 The annual rate of progression to dementia is approx- tic Reviews found that the sensitivities of the MMSE in
imately 5% to 17%.13-15,18 Some established biomarkers asso- detecting the progression from MCI to dementia ranged from
ciated with the progression from MCI to Alzheimer’s disease 23% to 76%, 27% to 89% for MCI to Alzheimer, and 36% for
are a positive amyloid positron emission tomography (PET) MCI to vascular dementia, and the corresponding specificities
scan, apolipoprotein E4 genotype, abnormal cerebrospinal were 40% to 94%, 32% to 90%, and 80%, respectively.33 At
fluid (CSF) tau levels, a positive PET scan due to tau deposition the cut points of 27 or 28 of the MMSE in detecting MCI, the
into the lateral temporal lobe structures.11-13,15,19,20 sensitivities were varied from 45% to 60% and the specifici-
ties were 65% to 90%.12
One systematic review showed that the area under the
Diagnosis of MCI receiver operating characteristic (ROC) curve of the MoCA
The diagnostic criteria for MCI include concern regarding a in detecting MCI at the cutoff point of 24/25 was 0.846 (95%
change in cognition, abnormal cognitive function in one or confidence interval [CI]: 0.823-0.868) with a sensitivity of
more domains, normal daily activity, and absence of demen- 80.48% and specificity of 81.19%. For the MMSE, the area
tia.13,21 A thorough interview regarding the patient’s history under the ROC curve at the cutoff point of 27/28 was 0.736
from knowledgeable informants in order to detect the clinical (95% CI: 0.718-0.767) with a sensitivity of 66.34% and spe-
clues is fundamental in making diagnosis. Adding appropriate cificity of 72.94%.27 A direct comparison of the MoCA and
cognitive screening tests is another crucial part for clinical the MMSE also reported that MoCA was more sensitive for
evaluation of patients with MCI. The Montreal Cognitive precisely differentiating persons with MCI from those with
Assessment (MoCA) with a cutoff point of 24/25 is the recom- normal cognitive function. 12 Although MoCA is recom-
mended cognitive screening tool for MCI. The sensitivity and mended primarily in MCI screening in several studies,9,16,27
specificity of the test have been found to be 80.48% and there are some limitations as described above; clinical judg-
81.19%, respectively.22 At the cutoff point of 25/26, it had ment including premorbid functioning such as intellectual
sensitivity of 80% and 100% and specificity of 50% to function and occupational status remains the essential ele-
76%.12 However, it does get affected by educational level, life- ments in diagnosing MCI.
style factors, and ethnic diversities.23,24 For example, the Can-
tonese Chinese version with a cutoff point of 22/23 showed a
sensitivity of 78% and specificity of 73% in detecting amnestic Pathogenesis and Outcomes of MCI
type of MCI.25 A study in Canada showed that adjusting the Dementia resulting from decades of proteinopathy, such as
MoCA total score for education decreased its overall sensitivity Alzheimer’s disease, is associated with amyloid-b deposition:
from 80% to 69% and small increment of specificity from 89% extraneuronally neuritic plaques and intracellularly neurofi-
to 92%, and at the best cutoff point of 24/25, it provided sensi- brillary tangles. For progressive supranuclear palsy, cortico-
tivity and specificity of 61% and 97%, respectively.23 basal degeneration, and frontotemporal lobar degeneration,
The Mini-Mental Status Examination (MMSE) and the they are classified as tauopathy, and for Lewy body dementia
Dementia Rating Scale (DRS) are not recommended as screen- and Parkinson disease dementia, they are synucleinopathy.34
ing tools for MCI due to their limitations with regard to detect- However, there are other important factors in the pathogenesis
ing abnormal cognitive function. 22,26 The potential of dementia such as sedentary lifestyle, poor nutritional sta-
explanations regarding the limitation of the MMSE perfor- tus, social or environmental factors, and genetic factors that
mances in detecting MCI are the cultural factors, educational could be modifiable.34
level, factors related to favored language use, and correlation of The various etiologies of MCI such as systemic diseases,
cognitive domains in early cognitive deficits. For example, the neurological diseases, medications, and psychiatric disorders
502 American Journal of Alzheimer’s Disease & Other Dementias® 33(8)
Table 1. Core Clinical Criteria of MCI Due to Alzheimer’s Disease. Table 2. Biomarkers for Alzheimer’s Disease.14,16
Table 3. Classification of Mild Cognitive Impairment.16 Table 4. Proposed Diagnostic Criteria for Vascular Cognitive
Impairment and Vascular Dementia.53,55,58
Classification Definition
Dementia (vascular dementia [VaD])
High likelihood Presence of the core clinical symptoms
and both amyloid-b and neuronal Definite Impaired cognitive function in 2 or more cognitive
damage biomarkers are present domains, which affects social and occupational
Intermediate likelihood Presence of the core clinical symptoms function independent of any motor or sensory
and a single positive biomarker (either deficits from a stroke (if present)
amyloid deposition or neuronal Cognitive domains: executive/attention, language,
damage) memory, visuospatial functions
Unlikely to be due to Presence of the core clinical symptoms but Probable No history of impaired cognitive function during a
Alzheimer’s disease neither types of biomarkers cerebrovascular event which might be due to
neurodegenerative disease and is characterized by
impaired cognition with imaging evidence of
cerebrovascular disease and a temporal association
naproxen), ginkgo biloba, vitamin E, or vitamin E plus vitamin C between the onset of stroke and cognitive symptoms, or
have any benefit in this regard. Similarly, flavonoid-containing clear evidence of a temporal association between
drink, homocysteine-lowering B vitamins, and V0191 showed cognitive impairment and the presence of diffuse,
insufficient results on cognitive measures.9 A 6-month of trans- subcortical cerebrovascular pathology
dermal nicotine (15 mg/d) were likely to gain cognitive test per- Possible No clear relationship between cerebrovascular events
formance but not clinical global impression in patients with MCI (chronic ischemia, subclinical brain infarction [SBI], white
who did not smoke.9,48 In addition, receiving tesamorelin (growth matter disease from small-vessel disease) and cognitive
impairment. Alternatively, there may not be adequate
hormone–releasing hormone) injections over 20 weeks might be imaging information available or the severity of some
effective in promoting performance on various cognitive mea- neurological deficits (such as aphasia) may preclude proper
sures, but the sustainability of this effect after 20 weeks was cognitive testing, and there may be evidence of underlying
uncertain.9,49 Cognitive and physical activity have been shown neurodegenerative disorders such as Alzheimer’s disease,
to decrease the risk of dementia and MCI, but more evidence of Parkinson disease, progressive supranuclear palsy,
this is necessary.14 The benefit of exercise was derived from 2 dementia with Lewy bodies, or the presence of systemic
studies. One was a 6-month randomized controlled trial of twice- diseases such as cancer, or metabolic disorders that may be
associated with cognitive dysfunction.
weekly resistance training exercise; the results showed improved
selective attention/conflict resolution, associative memory, and Vascular mild cognitive impairment (VaMCI)
Definite Impaired cognitive function in at least 1 cognitive
regional patterns of functional brain plasticity, compared with domain without or with minimal effect on social and
twice-weekly balance and tone exercises in patients with MCI. occupational function independent of any motor or
It was a 60-minute class under certified fitness instructors. The sensory deficit from a stroke (if present).
patients performed 2 sets of 6 to 8 repetitions and loading Four main categories are defined: amnestic,
increased when sets were accomplished with appropriate form.50 amnestic plus other domains, nonamnestic single
Another study also demonstrated that multicomponent exercise domain, nonamnestic multiple domains
could improve logical memory and preserve usual cognitive func- Possible Same as the “possible” definition above
Probable Same as the “probable” definition above
tion in patients with MCI. The patients performed 90 minutes/d,
40 times for 6 months.9,10 For cognitive intervention, the evidence
is currently insufficient to support or disprove the use of any
individual one. It may promote strategy knowledge, internal strat- vascular damage found using neuroimaging.53 There are mul-
egy use, and well-being but not external strategy or memory.9 A tiple domains of cognitive deficits in cases of VCI that have
systematic review and meta-analysis reported that cognitive inter- common presentations with dysexecutive syndrome.18,54,55
ventions may impact not only on cognitive outcomes alone but Concomitant motor signs with VCI include frontal gait distur-
also on activities of daily living and metacognition.51 Therefore, bance, lower body parkinsonism, apathy, depression, urinary
encouraging patients with MCI perform regular physical and incontinence, spasticity, hyperreflexia, and frontal release
cognitive exercise training is recommended.9 signs.52 Majority of VCI would be mixed type, with the most
common combined with Alzheimer’s disease.
Modification of various vascular risks may potentially
Vascular Cognitive Impairment reduce the risk of nonamnestic MCI.56 The pathogenesis of
Vascular MCI or VCI is a type of MCI that is unlikely to be due VCI depends on host factors (age, education, genetics, ApoE-
to Alzheimer’s disease. It is commonly classified into 2 cate- 4 carrier, vascular risk factors, diabetes), vascular causes
gories namely, poststroke- and nonstroke-related VCI.52 Vas- (atherosclerosis, microvascular diseases, endothelial disorder),
cular cognitive impairment consists of one or more cognitive and additional pathologies (amyloid deposition, cerebral amy-
impairments including executive/attention, memory, language, loid angiopathy, aging).56,57 There have been criteria proposed
and visuospatial functions, ranging from MCI to dementia, for diagnosis of VCI and vascular dementia, and these are
caused by clinical features of vascular events or evidence of presented in Table 4 according to the American Heart
504 American Journal of Alzheimer’s Disease & Other Dementias® 33(8)
Association/American Stroke Association.53,55,58 Diagnostic Table 5. Issues to Consider in the Diagnosis of PD-MCI.60
criteria are based on the presence of cognitive deficit and vas-
No. Issues
cular disease plus a clinical decision that the cerebrovascular
lesions explain the deficit in the affected patient.52 There are 1 Availability of subjective and objective data from sources
various modifiable risk factors for VCI, the amelioration of including the patient, informant, clinician, and
which can decrease the degree of vascular injury. neuropsychological tests
There are abundant studies regarding the benefit of cholines- 2 Initial versus serial evaluations
3 Clinical information
terase inhibitors and the N-methyl-D-aspartate (NMDA) receptor
a) Presence of cognitive (not only memory) complaints and
antagonist in VCI. Overall, they were safe and improved modest by whom (patient, informant, clinician)
cognitive advantages, with inconsistent benefit on overall func- b) Assessment of functioning in activities of daily living and
tion.52,53 Other pharmacological treatment showed insufficient differentiating cognitive effects from motor impairment
evidence on cognitive measures such as aspirin, calcium channel c) Presence of comorbid nonmotor features: depression,
blockers, statin, and vitamin supplementation.53,59 Treatment of anxiety, apathy, psychosis, fatigue, sleep disturbances, and their
hypertension and lifestyle modification, such as being active and impact on cognition and during neuropsychological tests
4 Neuropsychological testing
engaging in regular exercise, getting adequate nutrition, main-
a) Selection of specific cognitive tests or screening
taining adequate socioeconomic support from the community, instruments, use of normative data, and cutoff scores
avoiding inappropriate use of medication, avoiding smoking, b) Motor state (“on” versus “off”) during neuropsychological
adherence to a Mediterranean diet, moderation of alcohol con- testing
sumption, and adopting a positive attitude, may be effective stra- c) Motor demands of some neuropsychological tests
tegies to prevent or delay the progression to vascular dementia45; d) Effect of mood disorders, psychosis, fatigue, and daytime
however, there is limited evidence of these interventions in sleepiness on neuropsychological test performance
improving cognitive function in patients with VCI.59 Benefits Abbreviation: PD-MCI, mild cognitive impairment in Parkinson disease.
of physical activity is probably due to the results of synaptogen-
esis, neurogenesis, and promoting vascular health similarly to the
effect on other causes of dementia.53 The consequence of low- Diagnosis of PD-MCI is presented in Table 5.60 Use of the MoCA
ering blood pressure to prevent cognitive decline beyond stroke as a screening tool for this syndrome has been recommended, as it
prevention is debated; however, treating high blood pressure in is validated for both MCI and Parkinson’s disease with dementia.62
persons with hypertension is generally advised due to benefit on Nonpharmacological measures for MCI in Parkinson disease,
other aspects. Focusing on hyperglycemia, there was small evi- such as cognitive intervention programs or physical exercise,
dence regarding the effect on reducing VCI risk in diabetic require further investigation. There is little evidence of cholines-
patients. Given its benefit on various target organs including terase inhibitors reducing the risk of falling and improving cog-
heart, eye and kidney, appropriate glycemic control in diabetic nitive outcomes in patients with Parkinson disease using
patients is likely to be worthwhile.53 donepezil or memantine.60,62 Dopaminergic medications such
as levodopa or dopamine agonists showed inconstant cognitive
effects depending on the nature of task and level of basal dopa-
Mild Cognitive Impairment in Parkinson mine function in corticostriatal circuitry.63 A 24-week, double-
Disease blind, placebo-controlled trial of Rasagiline (a monoamine
Parkinson disease is the second most common neurodegenera- oxidase type B inhibitor) treatment in PD-MCI failed to improve
tive disorder with progressive loss of dopaminergic neurons of cognitive function, but it gained motor symptoms and activities
the substantia nigra pars compacta.57 Mild cognitive impair- of daily living.64 Atomoxetine, a adrenergic reuptake inhibitor,
ment in Parkinson disease (PD-MCI) usually takes the form of clozapine, serotonin and dopamine receptors, and second-
nonamnestic single-domain MCI and leads to increased health- generation tricyclic antidepressant were found to enhance atten-
care costs, increased fall risk, lower quality of life, and disabil- tion and better control psychosis and depressed mood from
ities. Risk factors for MCI in Parkinson disease are aging, placebo-controlled trials.65 Management of comorbidities, such
severe motor symptoms, non-tremor-dominant motor pheno- as depression, anxiety, apathy, and sleep disorder, which can
type, and low education. The prevalence of MCI in Parkinson contribute to worsening of cognitive function appears to be help-
disease is about 20% to 50%; it varies depending on the pop- ful. Furthermore, non-PD medications, such as centrally acting
ulation, cognitive domain, and utilized definition.60,61 medications for pain, bladder function, and sleep, which causes
The pathophysiology of MCI in Parkinson disease may include cognitive decline should be avoided.60
synucleinopathy and amyloid deposition, neurochemical dysfunc-
tion (acetylcholine and dopamine), synaptic loss, and structural
change. These processes are no different from Alzheimer’s dis-
Can MCI Be Prevented?
ease, as they begin with slowly progressive proteinopathy and Mild cognitive impairment may progress to dementia, and
progress to cellular dysfunction and, eventually, structural approved medications at present could only delay the progres-
change.48-50 There has been a criterion proposed for the diagnosis sion of some types of dementia, particularly Alzheimer’s dis-
of MCI in Parkinson’s disease,51 but it still needs validation. ease. Additionally, the effects of medications are modest.12,29
Jongsiriyanyong and Limpawattana 505
6. Ruan Q, Yu Z, Chen M, Bao Z, Li J, He W. Cognitive frailty, a 24. O’Driscoll C, Shaikh M. Cross-cultural applicability of the Mon-
novel target for the prevention of elderly dependency. Ageing Res treal Cognitive Assessment (MoCA): a systematic review. J Alz-
Rev. 2015;20:1-10. heimers Dis. 2017;58(3):789-801.
7. Feng L, Zin Nyunt MS, Gao Q, Feng L, Yap KB, Ng TP. Cogni- 25. Chu LW, Ng KH, Law AC, Lee AM, Kwan F. Validity of the
tive frailty and adverse health outcomes: findings from the Sin- Cantonese Chinese Montreal Cognitive Assessment in Southern
gapore Longitudinal Ageing Studies (SLAS). J Am Med Dir Chinese. Geriatr Gerontol Int. 2015;15(1):96-103.
Assoc. 2017;18(3):252-258. 26. Matallana D, de Santacruz C, Cano C, et al. The relationship
8. Hazzard WR, Halter JB. Hazzard’s Geriatric Medicine and Ger- between education level and mini-mental state examination
ontology. 6th ed. New York, NY: McGraw-Hill; 2009. domains among older Mexican Americans. J Geriatr Psychiatry
9. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline Neurol. 2011;24(1):9-18.
update summary: mild cognitive impairment: report of the guide- 27. Ciesielska N, Sokolowski R, Mazur E, Podhorecka M, Polak-
line development, dissemination, and implementation subcom- Szabela A, Kedziora-Kornatowska K. Is the Montreal Cognitive
mittee of the American Academy of Neurology. Neurology. Assessment (MoCA) test better suited than the Mini-Mental State
2018;90(3):126-135. Examination (MMSE) in mild cognitive impairment (MCI) detec-
10. Suzuki T, Shimada H, Makizako H, et al. A randomized con- tion among people aged over 60? Meta-analysis. Psychiatr Pol.
trolled trial of multicomponent exercise in older adults with mild 2016;50(5):1039-1052.
cognitive impairment. Plos One. 2013;8(4):e61483. 28. Shim YS, Yang DW, Kim HJ, Park YH, Kim S. Characteristic
11. Cheng YW, Chen TF, Chiu MJ. From mild cognitive impairment differences in the mini-mental state examination used in Asian
to subjective cognitive decline: conceptual and methodological countries. BMC Neurol. 2017;17(1):141.
evolution. Neuropsychiatr Dis Treat. 2017;13:491-498. 29. Duara R, Loewenstein DA, Greig-Custo MT, et al. Diagnosis and
12. Langa KM, Levine DA. The diagnosis and management of mild staging of mild cognitive impairment, using a modification of the
cognitive impairment: a clinical review. JAMA. 2014;312(23): clinical Dementia Rating Scale: the mCDR. Int J Geriatr Psy-
2551-2561. chiatry. 2010;25(3):282-289.
13. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, 30. Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D.
Kokmen E. Mild cognitive impairment: clinical characterization Clinical prediction of Alzheimer disease dementia across the
and outcome. Arch Neurol. 1999;56(3):303-308. spectrum of mild cognitive impairment. Arch Gen Psychiatry.
14. Petersen RC. Mild cognitive impairment. Continuum (Minneap 2007;64(12):1443-1450.
Minn). 2016;22(2 Dementia):404-418. 31. Woolf C, Slavin MJ, Draper B, et al. Can the clinical Dementia
15. Li JQ, Tan L, Wang HF, et al. Risk factors for predicting progres- Rating Scale identify mild cognitive impairment and predict cog-
sion from mild cognitive impairment to Alzheimer’s disease: a nitive and functional decline? Dement Geriatr Cogn Disord.
systematic review and meta-analysis of cohort studies. J Neurol 2016;41(5-6):292-302.
Neurosurg Psychiatry. 2016;87(5):476-484. 32. Chang YL, Bondi MW, McEvoy LK, et al. Global clinical demen-
16. Lopez OL. Mild cognitive impairment. Continuum (Minneap tia rating of 0.5 in MCI masks variability related to level of
Minn). 2013;19(2 Dementia):411-424. function. Neurology. 2011;76(7):652-659.
17. Prestia A, Caroli A, van der Flier WM, et al. Prediction of demen- 33. Arevalo-Rodriguez I, Smailagic N, Roque IFM, et al. Mini-
tia in MCI patients based on core diagnostic markers for Alzhei- Mental State Examination (MMSE) for the detection of Alzhei-
mer disease. Neurology. 2013;80(11):1048-1056. mer’s disease and other dementias in people with mild cognitive
18. Ganguli M, Fu B, Snitz BE, Hughes TF, Chang CC. Mild cogni- impairment (MCI). Cochrane Database Syst Rev. 2015(3):
tive impairment: incidence and vascular risk factors in a CD010783.
population-based cohort. Neurology. 2013;80(23):2112-2120. 34. Honig LS. Translational research in neurology: dementia. Arch
19. Yarnall AJ, Rochester L, Burn DJ. Mild cognitive impairment in Neurol. 2012;69(8):969-977.
Parkinson’s disease. Age Ageing. 2013;42(5):567-576. 35. Sachdev PS, Lipnicki DM, Crawford J, et al. Factors predicting
20. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progres- reversion from mild cognitive impairment to normal cognitive
sion of mild cognitive impairment to dementia in clinic- vs functioning: a population-based study. Plos One. 2013;8(3):
community-based cohorts. Arch Neurol. 2009;66(9):1151-1157. e59649.
21. Nelson AP, O’Connor MG. Mild cognitive impairment: a neurop- 36. Koepsell TD, Monsell SE. Reversion from mild cognitive impair-
sychological perspective. CNS Spectr. 2008;13(1):56-64. ment to normal or near-normal cognition: risk factors and prog-
22. Espino DV, Lichtenstein MJ, Palmer RF, Hazuda HP. Ethnic nosis. Neurology. 2012;79(15):1591-1598.
differences in Mini-Mental State Examination (MMSE) scores: 37. Plaza-Zabala A, Sierra-Torre V, Sierra A. Autophagy and micro-
where you live makes a difference. J Am Geriatr Soc. 2001;49(5): glia: novel partners in neurodegeneration and aging. Int J Mol Sci.
538-548. 2017;18(3):E598.
23. Gagnon G, Hansen KT, Woolmore-Goodwin S, et al. Correcting 38. Koellhoffer EC, McCullough LD, Ritzel RM. Old maids: aging
the MoCA for education: effect on sensitivity. Can J Neurol Sci. and its impact on microglia function. Int J Mol Sci. 2017;18(4):
2013;40(5):678-683. E769.
Jongsiriyanyong and Limpawattana 507
39. Karakaya T, Fusser F, Schroder J, Pantel J. Pharmacological treat- 54. Sudo FK, Alves CEO, Alves GS, et al. Dysexecutive syndrome
ment of mild cognitive impairment as a prodromal syndrome of and cerebrovascular disease in non-amnestic mild cognitive
Alzheimer’s disease. Curr Neuropharmacol. 2013;11(1):102-108. impairment: a systematic review of the literature. Dement Neu-
40. Barnes DE, Santos-Modesitt W, Poelke G, et al. The Mental ropsychol. 2012;6(3):145-151.
Activity and eXercise (MAX) trial: a randomized controlled trial 55. Rincon F, Wright CB. Vascular cognitive impairment. Curr Opin
to enhance cognitive function in older adults. JAMA Intern Med. Neurol. 2013;26(1):29-36.
2013;173(9):797-804. 56. Chawalparit O, Wonglaksanapimon S, Songsaeng D, Saenanar-
41. Lowry KA, Vallejo AN, Studenski SA. Successful aging as a ong V. Reliability study of white matter rating scale for the
continuum of functional independence: lessons from physical dis- dementia and disability in Thai Elderly Project. J Med Assoc Thai.
ability models of aging. Aging Dis. 2012;3(1):5-15. 2009;92(4):543-547.
42. Petersen RC.Clinical practice. Mild cognitive impairment. N Engl 57. Jellinger KA. Pathology and pathogenesis of vascular cognitive
J Med. 2011;364(23):2227-2234. impairment-a critical update. Front Aging Neurosci. 2013;5:17.
43. Jack CR Jr., Knopman DS, Jagust WJ, et al. Tracking pathophy- 58. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to
siological processes in Alzheimer’s disease: an updated hypothe- cognitive impairment and dementia: a statement for healthcare
tical model of dynamic biomarkers. Lancet Neurol. 2013;12(2): professionals from the American Heart Association/American
207-216. Stroke Association. Stroke. 2011;42(9):2672-2713.
44. Leclerc B, Abulrob A. Perspectives in molecular imaging using 59. Ritter A, Pillai JA. Treatment of vascular cognitive impairment.
staging biomarkers and immunotherapies in Alzheimer’s disease. Curr Treat Options Neurol. 2015;17(8):367.
ScientificWorldJournal. 2013;2013:589308. 60. Goldman JG, Litvan I. Mild cognitive impairment in Parkinson’s
45. Budson AE, Solomon PR. New diagnostic criteria for Alzhei- disease. Minerva Med. 2011;102(6):441-459.
61. Monastero R, Cicero CE, Baschi R, et al. Mild cognitive impair-
mer’s disease and mild cognitive impairment for the practical
ment in Parkinson’s disease: the Parkinson’s Disease Cognitive
neurologist. Pract Neurol. 2012;12(2):88-96.
Study (PACOS). J Neurol. 2018;265(5):1050-1058.
46. Grimmer T, Wutz C, Drzezga A, et al. The usefulness of amyloid
62. Meireles J, Massano J. Cognitive impairment and dementia in
imaging in predicting the clinical outcome after two years in
Parkinson’s disease: clinical features, diagnosis, and manage-
subjects with mild cognitive impairment. Curr Alzheimer Res.
ment. Front Neurol. 2012;3:88.
2013;10(1):82-85.
63. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or
47. Fitzpatrick-Lewis D, Warren R, Ali MU, Sherifali D, Raina P.
impaired cognitive function in Parkinson’s disease as a function
Treatment for mild cognitive impairment: a systematic review
of dopaminergic medication and task demands. Cereb Cortex.
and meta-analysis. CMAJ Open. 2015;3(4):E419-E427.
2001;11(12):1136-1143.
48. Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild
64. Weintraub D, Hauser RA, Elm JJ, et al. Rasagiline for mild cog-
cognitive impairment: a 6-month double-blind pilot clinical trial.
nitive impairment in Parkinson’s disease: a placebo-controlled
Neurology. 2012;78(2):91-101.
trial. Mov Disord. 2016;31(5):709-714.
49. Baker LD, Barsness SM, Borson S, et al. Effects of growth
65. Yang Y, Tang BS, Guo JF. Parkinson’s disease and cognitive
hormone-releasing hormone on cognitive function in adults with impairment. Parkinsons Dis. 2016;2016:6734678.
mild cognitive impairment and healthy older adults: results of a 66. Brasure M, Desai P, Davila H, et al. Physical activity interven-
controlled trial. Arch Neurol. 2012;69(11):1420-1429. tions in preventing cognitive decline and Alzheimer-type demen-
50. Walker S, Hulmi JJ, Wernbom M, et al. Variable resistance train- tia: a systematic review. Ann Intern Med. 2018;168(1):30-38.
ing promotes greater fatigue resistance but not hypertrophy versus 67. Butler M, McCreedy E, Nelson VA, et al. Does cognitive training
constant resistance training. Eur J Appl Physiol. 2013;113(9): prevent cognitive decline?: a systematic review. Ann Intern Med.
2233-2244. 2018;168(1):63-68.
51. Chandler MJ, Parks AC, Marsiske M, Rotblatt LJ, Smith GE. 68. Butler M, Nelson VA, Davila H, et al. Over-the-counter supple-
Everyday impact of cognitive interventions in mild cognitive ment interventions to prevent cognitive decline, mild cognitive
impairment: a systematic review and meta-analysis. Neuropsy- impairment, and clinical Alzheimer-type dementia: a systematic
chol Rev. 2016;26(3):225-251. review. Ann Intern Med. 2018;168(1):52-62.
52. Smith E. Vascular cognitive impairment. Continuum (Minneap 69. Fink HA, Jutkowitz E, McCarten JR, et al. Pharmacologic inter-
Minn). 2016;22(2 Dementia):490-509. ventions to prevent cognitive decline, mild cognitive impairment,
53. Dichgans M, Leys D. Vascular cognitive impairment. Circ Res. and clinical Alzheimer-type dementia: a systematic review. Ann
2017;120(3):573-591. Intern Med. 2018;168(1):39-51.